Supernus Pharmaceuticals
SUPN
266 hedge funds and large institutions have $2.07B invested in Supernus Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 101 increasing their positions, 94 reducing their positions, and 24 closing their positions.
83% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 24
45% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $9.15M
44% more capital invested
Capital invested by funds: $1.44B → $2.07B (+$630M)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
8% more funds holding
Funds holding: 247 → 266 (+19)
4.33% more ownership
Funds ownership: 91.94% → 96.27% (+4.3%)
7% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$26.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$20.5M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$17.7M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$20.1M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$14.4M |
| 3 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$13.1M |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$9.08M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$7.45M |
SUPN Hedge Fund Activity: Q2 2017 in Review
266 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2017, worth a combined $2.07B — up 44% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new SUPN positions and 24 closed out — a net gain of 20 holders — while 101 added to existing stakes and 94 trimmed.
The largest buyer was Vanguard Group, adding an estimated $35M. The largest seller was Millennium Management, cutting an estimated $20.1M.
- 266 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2017, up from 247 in Q1 2017.
- Funds reported $2.07B of Supernus Pharmaceuticals stock for Q2 2017, up 44% quarter-over-quarter.
- 44 funds opened new Supernus Pharmaceuticals positions in Q2 2017 and 24 closed out, a net change of +20 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2017 was Vanguard Group, an estimated $35M added.
- The largest Supernus Pharmaceuticals seller in Q2 2017 was Millennium Management, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2017.